BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 26874581)

  • 1. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus Vector Harboring the HBcAg and Tripeptidyl Peptidase II Genes Induces Potent Cellular Immune Responses In Vivo.
    Tan Q; Ma S; Hu J; Chen X; Yu Y; Tang Z; Zang G
    Cell Physiol Biochem; 2017; 41(2):423-438. PubMed ID: 28214886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Tang Z; Zang G
    Acta Biochim Biophys Sin (Shanghai); 2015 Nov; 47(11):870-9. PubMed ID: 26373843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances HBV-specific humoral and CTL immune responses in vivo.
    Song L; Zhuo M; Tang Y; Chen X; Tang Z; Zang G
    Int Immunopharmacol; 2014 Nov; 23(1):1-7. PubMed ID: 25135878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice.
    Zhuo M; Song L; Tang Y; Dai S; Chen X; Yu Y; Zang G; Tang Z
    Mol Med Rep; 2015 Sep; 12(3):3591-3598. PubMed ID: 26004262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen.
    Chen JH; Yu YS; Chen XH; Liu HH; Zang GQ; Tang ZH
    World J Gastroenterol; 2012 Mar; 18(12):1319-27. PubMed ID: 22493545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Engineered DC-Targeting Lentivector Induces Robust T Cell Responses and Inhibits HBV Replication in HBV Transgenic Mice via Upregulating T Cell Autophagy.
    Ma S; Chen X; Tan Q; Dai S; Li D; Wu S; Yu Y; Zang G; Tang Z
    Cell Physiol Biochem; 2018; 48(3):1041-1059. PubMed ID: 30041239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
    Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
    Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice.
    Chen X; Lai J; Pan Q; Tang Z; Yu Y; Zang G
    Vaccine; 2010 May; 28(23):3913-9. PubMed ID: 20394723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with lentiviral vector‑modified dendritic cells encoding ubiquitinated hepatitis B core antigen promotes Th1 differentiation and antiviral immunity by enhancing p38 MAPK and JNK activation in HBV transgenic mice.
    Dai S; Chen X; Yu Y; Zang G; Tang Z
    Mol Med Rep; 2018 Nov; 18(5):4691-4699. PubMed ID: 30221736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal route favors the induction of CD4
    Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
    Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/Kb transgenic mice.
    Zhang Y; Li S; Shan M; Pan X; Zhuang K; He L; Gould K; Tien P
    Immunology; 2007 May; 121(1):105-12. PubMed ID: 17244158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion protein of tapasin and hepatitis B core antigen 18‑27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice.
    Tang Y; Chen X; Zhang Y; Tang Z; Zhuo M; Li D; Wang P; Zang G; Yu Y
    Mol Med Rep; 2014 Apr; 9(4):1171-8. PubMed ID: 24535102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice.
    Wang S; Han Q; Zhang N; Chen J; Liu Z; Zhang G; Li Z
    Immunol Lett; 2010 Jan; 127(2):143-9. PubMed ID: 19883689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.
    Chen X; Tang Y; Zhang Y; Zhuo M; Tang Z; Yu Y; Zang G
    Lab Invest; 2014 May; 94(5):478-90. PubMed ID: 24614195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.